The Times Australia
Google AI
Health

.

Ivermectin is still not a miracle cure for COVID-19, despite what you may have read

  • Written by Andrew McLachlan


The head lice drug ivermectin has yet again been touted in the media as a possible treatment for COVID-19. But despite the favourable headlines, huge uncertainty remains about whether this treatment can be safely and effectively repurposed to tackle the coronavirus.

In recent weeks the media has been awash with claims ivermectin, when given in combination with the common antibiotic doxycycline and zinc supplements, is effectively a “cure” for COVID-19.

Yet there has been no definitive clinical trial so far showing this is the case. All we have are observational studies and clinicians’ opinions.

The World Health Organisation’s database of clinical studies for COVID-19 shows there are currently 16 trials investigating ivermectin. Even these studies are unlikely to provide the high-quality data necessary to show ivermectin can actually provide its touted benefits.

Get your news from people who know what they’re talking about.

Many of the current studies have low numbers of participants, weak study designs, and inconsistent (and relatively low) ivermectin dosing regimes, with ivermectin frequently given in combination with other drugs.

The Royal Australian Council of General Practitioners and the Australian Commission for Quality and Safety in Health Care have warned there is insufficient evidence ivermectin is a safe and effective treatment for people infected with the coronavirus.

What do we know about ivermectin for COVID-19?

Laboratory studies using monkey cells in a test tube (as opposed to clinical studies in human patients) have shown ivermectin can shut down the replication of SARS-CoV-2, the coronavirus that causes COVID-19, within 24-48 hours of exposure to the drug.

Ivermectin is thought to inhibit the virus by preventing viral proteins moving in and out of the host cell’s nucleus, which is essential for replication of the coronavirus.


Read more: Head lice drug Ivermectin is being tested as a possible coronavirus treatment, but that's no reason to buy it


The problem is this process requires very high concentrations of ivermectin – well above the recommended dose for humans. This means ivermectin’s virus-killing powers would be unlikely to be harnessed inside the human body.

A detailed analysis of the relationship between dose and concentration of ivermectin suggests none of the currently used ivermectin dosing regimens would deliver high enough concentrations of ivermectin inside the body to activate its virus-killing effects.

Another review backs this up, suggesting all of the ivermectin doses being investigated in current clinical trials would fall well short of achieving drug concentrations high enough to wipe out SARS-CoV-2.

Even a 120 mg dose of ivermectin, which would be regarded as excessive (compared with the recommended dose of 3-15mg for treating parasitic infections) resulted in blood concentrations several orders of magnitude times lower than those needed to inhibit the virus.

Head louse on human hair
Great for killing head lice, but the jury’s still out on coronavirus. GillesSM/Wikimedia Commons, CC BY-SA

How much ivermectin is too much?

While ivermectin generally doesn’t cause problematic side effects at the currently used doses, there is limited information about whether much larger doses would also be safe.

Repurposing ivermectin as a “cure” for COVID-19 would require massive doses, which would substantially increase the risk of side effects such as nausea, rash, dizziness, immune suppression, abdominal pain, fever, raised heart rate and unstable blood pressure.

Ivermectin at usual doses does not enter the central nervous system, but after large doses of the drug it may enter the brain, potentially causing impaired vision, hampering the central nervous system (which could in turn affect breathing, heart rate and consciousness), and exaggerating the effects of other sedative medicines such as benzodiazepines.


Read more: Tested positive for COVID-19? Here's what happens next – and why day 5 is crucial


Ivermectin is a hugely useful medicine in treating parasitic illnesses such as lice, worms and scabies, particularly in developing countries. But as we have already seen in the case of the malaria drug hydroxychloroquine, just because a medicine is useful for one purpose, it cannot automatically be considered a miracle cure for COVID-19.

Repurposing drugs as COVID-19 treatments

Repurposing existing drugs as possible COVID-19 treatments is a smart strategy, but requires several key principles to be addressed. The drug must have antiviral effects in cells and animals at doses relevant to humans. The drug must be able to get to the site of infection in the body (or reduce the inflammation associated with the infection). It is best if the antiviral mechanism is understood. And finally, well designed clinical trials are needed to be sure the drugs works in people with the infection and it is safe to use (especially in older, vulnerable unwell people).

Thankfully, Australia’s National COVID-19 Clinical Evidence Taskforce continually assesses and updates the best evidence-based advice for treating COVID-19, which you can read here.

This article first appeared in The Conversation. It was republished with permission.

Times Magazine

Epson launches ELPCS01 mobile projector cart

Designed for the EB-810E[1] projector and provides easy setup for portable displays in flexible ...

Governance Models for Headless CMS in Large Organizations

Where headless CMS is adopted by large enterprises, governance is the single most crucial factor d...

Narwal Freo Z10 Robotic Vacuum and Mop Cleaner

Narwal Freo Z10 Robotic Vacuum and Mop Cleaner  Rating: ★★★★☆ (4.4/5) Category: Premium Robot ...

Shark launches SteamSpot - the shortcut for everyday floor mess

Shark introduces the Shark SteamSpot Steam Mop, a lightweight steam mop designed to make everyda...

Game Together, Stay Together: Logitech G Reveals Gaming Couples Enjoy Higher Relationship Satisfaction

With Valentine’s Day right around the corner, many lovebirds across Australia are planning for the m...

AI threatens to eat business software – and it could change the way we work

In recent weeks, a range of large “software-as-a-service” companies, including Salesforce[1], Se...

The Times Features

How Modern Specialist Accommodation is Redefining Accessible Living

For decades, the concept of accessible housing was synonymous with clinical functionality. The foc...

Insolvencies have spiked – would a law change let more businesses trade their way out of trouble?

New Zealand has been experiencing a striking rise in company failures, focusing attention on t...

The New Inheritance Problem Costing Australian Families Their Wealth

Australians are sleepwalking into a digital inheritance crisis by failing to include provisions fo...

Resmed’s Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach

Insights from 30,000 people across 13 countries, including Australia, show global sleep health aware...

Seeing the same midwife or doctor in pregnancy and labour reduces the risk of birth trauma

Every pregnant woman wants to deliver a healthy baby. During labour and birth, women also want...

Cobram Estate | Heart Health Month Backed By Science

A dedicated time to elevate awareness of cardiovascular wellbeing and support healthier lifestyles...

Heidi Launches Evidence and Acquires AutoMedica to Accelerate Its AI Care Partner Platform

New evidence layer and UK acquisition expand Heidi’s role across the clinical workflow Heidi, the...

OUTRIGGER Resorts & Hotels Elevates Wellness Travel in 2026 With Immersive New Programs in the Maldives

Movement, mindfulness and hands-on rituals anchor a renewed wellness focus at OUTRIGGER Maldives Maa...

Major maintenance dredging campaign begins at Port of Devonport

TasPorts will begin a major maintenance dredging campaign at the Port of Devonport next week, su...